The Science Behind GC7X® Turns HeadsBuy Now
GC7X® is the result of years of research tied to natural flavanoids. The impressive clinical studies for GC7X® were conducted by two of the world’s most prestigious research institutions: Eurofins and DGD, Cetero Labs.
Roots In Citrus and Supercomputers
Being tied to the citrus industry for decades, biochemists Daryl Thompson and Dr. Joe Ahrens always had a hunch that certain natural compounds found in tropical fruits offered tremendous metabolic benefits. With several family members suffering with diabetes and other symptoms of metabolic syndrome, they had extra incentive to try to unravel this mystery. Observing that natural citrus juices and other tropical fruit were higher in sugar than soda, yet consumption did not appear to lead to weight gain or diabetes, the researchers theorized that some component in tropical fruit had a direct effect on carbohydrate metabolism. Over several years, Dr. Ahrens & Thompson rented time on supercomputers from UCLA dissecting the components of over 700 fruit species in an effort to identify the phytochemicals that could potentially be causing these effects.
Hard Work Pays Off
At long last, in late 2006 Ahrens and Thompson completed their search and identified a group of three phytochemicals that combined in certain ratios seemed to be very promising in regards to their effect on metabolic functions. The phytochemicals identified appeared to address most of the metabolic disorders in the “Ominous Octet” identified by Dr. Ralph DeFronzo. The combination was subsequently patented. Because this combination emulated insulin at several key enzymatic control points and increased insulin sensitivity, it was trademarked under the name Emulin®.
Put To The Test
On paper, the three phytochemicals identified through the intense research should have had positive effects on carbohydrate metabolism but the researchers needed proof. Thus, they informally tried the formulation on random individuals and measured blood glucose levels accordingly. Results were extremely favorable which meant that the compound needed to be taken to a higher degree of clinical scrutiny.
Eurofins – Premier Research Institution
The researchers didn’t want the results of their clinical studies to ever be questioned so they decided to go to the crème de la crème of research institutions: Eurofins Scientific SE (www.eurofins.com). Eurofins is well known throughout the world for the quality of their research.
The Results Are Very Promising
The Eurofins study involved 50 diabetic rats untreated with insulin and 10 “control” non-diabetic rats. The untreated rats were biologically unable to produce insulin on their own. The rats that received the Emulin® ingredient saw their blood sugars drop by more than 20%. The rats that received the placebo unfortunately died very quickly. The study was repeated by Eurofins and the same miraculous results were achieved leading principle Eurofins’ investigator Dr. Gary Glover to state “I have never seen anything perform like this in this severe of a model.”
Armed with phenomenal data from the Eurofins rat study, the researchers then took things to the next level: a full fledged human clinical study taken to a severe degree of scrutiny to ensure accuracy. Once again, the researchers wanted only the best of the best to conduct their research. After researching their options, the Diabetic and Glandular Disease Clinic (www.dgdclinic.com) in San Antonio, Texas was chosen due their familiarity with carbohydrate metabolism. At the time of the study, DGD Research was the largest privately owned national endocrine and metabolic research organization in the United States.
.More Positive Results
The DGD clinical study was designed to be bullet proof as it was a randomized, double-blind, placebo controlled parallel group human clinical study. 40 adult subjects were chosen to participate in the study. All subjects had a Body Mass Index of greater than 30. All subjects had been diagnosed with having Type 2 Diabetes (having a blood sugar level between 126 – 249 mg/dL). Like the rat study, the results were extremely positive. The results indicated that Emulin® can indeed impact blood glucose levels in Type 2 Diabetics by lowering blood glucose and peak glucose levels. Those subjects taking Emulin® alone had a 20% decline in fasting blood glucose levels within two weeks of starting the study, significantly outperforming the other two groups of subjects. Additionally, it was noted that participants lost more weight then that of the leading perscription weight loss drugs.
Dr. Mark Kipnes, the DGD Clinic principle investigator in charge of the Emulin® research project said it best when stating that “Emulin®….is a genuine breakthrough”. Few products in the natural product marketplace have been researched as thoroughly as the Emulin® compound found in GC7X™. No other product has shown such positive results in effectively improving overall carbohydrate metabolism. To positively affect blood glucose levels and overall carbohydrate metabolism, research gives credence to your GC7X® choice.